Synlogic has been granted a patent for genetically engineered bacteria and pharmaceutical compositions for modulating and treating diseases related to hyperphenylalaninemia. The patent also includes a claim for a mutant phenylalanine ammonia lyase (PAL) polypeptide with specific amino acid mutations compared to a wildtype PAL. GlobalData’s report on Synlogic gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Synlogic, Peptide pharmacophores was a key innovation area identified from patents. Synlogic's grant share as of September 2023 was 17%. Grant share is based on the ratio of number of grants to total number of patents.
Genetically engineered bacteria for treating hyperphenylalaninemia
A recently granted patent (Publication Number: US11766463B2) describes a mutant phenylalanine ammonia lyase (PAL) polypeptide with specific mutations compared to the wildtype Photorhabdus luminescens PAL. The mutant PAL polypeptide exhibits an increased ability to metabolize phenylalanine compared to the wildtype PAL.
The mutant PAL polypeptide described in the patent comprises one or more mutations at specific amino acid positions, including S92, H133, I167, L432, V470, A433, A263, K366, and L396. The mutations can be in various combinations, such as S92G; H133M; I167K; L432I; V470A, S92G; H133F; A433S; V470A, or S92G; H133F; A263T; V470A.
The patent claims that the mutant PAL polypeptide exhibits an increased ability to metabolize phenylalanine compared to the wildtype PAL. The extent of the increase is specified in multiple claims, ranging from at least two-fold to at least five-fold. This suggests that the mutant PAL polypeptide has a significantly enhanced capacity to break down phenylalanine, which could have potential applications in various fields.
Additionally, the patent includes a claim for a composition comprising the mutant PAL polypeptide. This composition could be used in various applications where the increased ability to metabolize phenylalanine is desired.
Overall, this granted patent describes a mutant PAL polypeptide with specific mutations that result in an increased ability to metabolize phenylalanine compared to the wildtype PAL. The patent claims cover the mutant polypeptide itself as well as a composition comprising it. The enhanced phenylalanine metabolism exhibited by the mutant PAL polypeptide could have significant implications in industries such as biotechnology, pharmaceuticals, and agriculture.
To know more about GlobalData’s detailed insights on Synlogic, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
